Sunho Biologics (HKSE:02898) Interest Expense : HK$-1.12 Mil (TTM As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Sunho Biologics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sunho Biologics's interest expense for the six months ended in Jun. 2024 was HK$ -0.61 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-1.12 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sunho Biologics's Operating Income for the six months ended in Jun. 2024 was HK$ -56.99 Mil. Sunho Biologics's Interest Expense for the six months ended in Jun. 2024 was HK$ -0.61 Mil. Sunho Biologics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sunho Biologics Interest Expense Historical Data

The historical data trend for Sunho Biologics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunho Biologics Interest Expense Chart

Sunho Biologics Annual Data

Trend

Dec22

Dec23

Interest Expense

-5.67

-0.76

Sunho Biologics Semi-Annual Data
	Dec22	Jun23	Dec23	Jun24
Interest Expense	-	-0.24	-0.52	-0.61

Sunho Biologics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-1.12 Mil.

Sunho Biologics (HKSE:02898) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sunho Biologics's Interest Expense for the six months ended in Jun. 2024 was HK$-0.61 Mil. Its Operating Income for the six months ended in Jun. 2024 was HK$-56.99 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2024 was HK$4.96 Mil.

Sunho Biologics's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as

Sunho Biologics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Sunho Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunho Biologics Inc (HKSE:02898) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 198 Peninsula Middle Road, Dipu Street, Room 302, Building 3, Anji County, Zhejiang Province, Huzhou, CHN

Website

http://www.sunho-bio.com.cn

Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.

Executives

Sunho Fortune Investments Limited	2201 Interest of corporation controlled by you
Trident Trust Company (hk) Limited	2301 Trustee
Zhang Feng	2201 Interest of corporation controlled by you
Sunho Wisdom Investments Limited	2101 Beneficial owner

Sunho Biologics Headlines

No Headlines